The common thread is the transition from innovation to industrial capability: developing a new therapy is only one part of the journey. Robust processes, scalable technologies, expertise, manufacturing capacity and quality systems are all needed to support increasingly complex products.
A major section of the magazine is dedicated to Advanced Therapy Medicinal Products, viewed from a manufacturing perspective. Starting materials and biological variability become part of the control strategy; closed systems, automation and single-use technologies are changing the way facilities are designed; scale-out is replacing traditional scale-up, while the manufacturing network itself becomes an integral part of the product.
Analytics is also taking on a different role. For advanced therapies, identity, purity and sterility are not enough: the product must also retain the biological function for which it was developed. This is why the issue focuses on potency, one of the most complex challenges in ATMP development and manufacturing.
The perspective then broadens to Europe and its ability to turn scientific excellence into industrial growth. Europe’s biotech challenge increasingly emerges after discovery: financing development, scaling up, building biomanufacturing capacity, and retaining expertise and value within the region.
Alongside the editorial features, the issue explores technologies and industry experience across engineering, equipment, qualification, packaging, analytical characterization and performance throughout the entire lifecycle, with contributions and perspectives from companies working every day in pharmaceutical manufacturing.
24 pages to look at CPHI not only as a technology showcase, but as a privileged vantage point on how the pharmaceutical industry is changing.
Want to explore all the features?
Visit us at CPHI Milan 2026, or browse the digital edition online.
Vuoi trovare più facilmente MakingPharmaIndustry su Google?
Aggiungici alle tue fonti preferite
